HTG, OvaGene Reach Assay Development Deal for Gynecologic Cancers | GenomeWeb

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics and OvaGene Oncology today announced a manufacturing supply agreement for the design and development of gene expression assays for gynecologic cancers on HTG's platform.

Under the terms of the deal, OvaGene will develop the assays on the HTG Edge System, an automated gene expression platform that delivers multiplexed results on lysed samples in less than one day. HTG launched the platform in 2013 with a portfolio of mRNA assays based on the company's proprietary nuclease protection chemistry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.